Table 4 Comparison of clinical and economic outcomes in subcohort of chronic ischemic heart disease
From: Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease
Outcome | Conventional treatment + salvianolate injection (n = 129) | Conventional treatment (n = 129) | Difference | P |
|---|---|---|---|---|
Hospital stay (d) | 11.9 (± 7.7) | 15.5 (± 13.0) | − 3.6 | < 0.05 |
Total nitrates dosage (mg) | 452.7 (± 490.1) | 703.4 (± 845.2) | − 250.7 | < 0.05 |
Total medical costs (CNY) | 12,694.9 (± 20,609.5) | 17,034.4 (± 21,251.3) | − 4339.5 | < 0.05 |
Subcategories costs (CNY) | Â | |||
 Supplies cost | 3760.4 (± 15,171.77) | 5158.4 (± 9740.56) | − 1398 | 0.382 |
 Pharmacy cost | 3308.2 (± 3660.5) | 4925.7 (± 5065.2) | − 1617.5 | < 0.05 |
 Examination cost | 1551.1 (± 1403.78) | 1957.2 (± 1742.96) | − 406.1 | < 0.05 |
 Laboratory cost | 1365.6 (± 823.26) | 1627.4 (± 1384.94) | − 261.8 | 0.07 |
 Operation cost | 2592.7 (± 2243.94) | 4705.1 (± 3228.53) | − 2112.4 | < 0.05 |
 Treatment cost | 462 (± 895.68) | 1042 (± 1678.62) | − 580 | < 0.05 |
 Chinese patent drug cost | 1334.9 (± 637.9) | 145.6 (± 378.8) | 1189.3 | < 0.05 |